BIOMAT Database Logo BIOMAT Database Logo

Malaria breakthrough despite chlorproguanil chemoprophylaxis in an area without antifol resistance. 1988

E Petersen, and B Høgh, and A P Hanson, and H Flachs
Malaria Research Unit Liberian Institute for Biomedical Research, Yekepa.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D002727 Proguanil A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent. Chlorguanid,Chloroguanide,Bigumal,Chloriguane,Chloroguanide Hydrochloride,Paludrin,Paludrine,Proguanil Hydrochloride,Hydrochloride, Chloroguanide,Hydrochloride, Proguanil
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines

Related Publications

E Petersen, and B Høgh, and A P Hanson, and H Flachs
Chlorproguanil chemoprophylaxis for falciparum malaria in Kenya.
March 1987, Lancet (London, England),
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Falciparum malaria despite chemoprophylaxis.
June 1979, British medical journal,
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Falciparum malaria despite chemoprophylaxis.
May 1979, British medical journal,
E Petersen, and B Høgh, and A P Hanson, and H Flachs
[Malaria chemoprophylaxis. Resistance problems].
December 1985, Archives francaises de pediatrie,
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya.
January 1987, Lancet (London, England),
E Petersen, and B Høgh, and A P Hanson, and H Flachs
[Malaria despite chemoprophylaxis: problems for diagnosis and therapy].
April 1986, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Double-blind study to assess the efficacy of chlorproguanil given alone or in combination with chloroquine for malaria chemoprophylaxis in an area with Plasmodium falciparum resistance to chloroquine, pyrimethamine and cycloguanil.
January 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene,
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Chlorproguanil-dapsone for malaria.
January 2004, Lancet (London, England),
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Chlorproguanil-dapsone for malaria.
January 2004, Lancet (London, England),
E Petersen, and B Høgh, and A P Hanson, and H Flachs
Malaria chemoprophylaxis: an update.
March 1987, Papua and New Guinea medical journal,
Copied contents to your clipboard!